Spravato® treatment (esketamine nasal spray) is an FDA-approved option for adults with treatment-resistant depression and depressive symptoms in adults experiencing suicidal ideation or behavior. For individuals who have not found relief with traditional antidepressants, Spravato® treatment can offer meaningful improvement when delivered appropriately. However, because Spravato® requires strict medical oversight, monitoring, and follow-up, not all clinics offering this treatment provide the same level of care.
As Spravato® treatment becomes more widely available, patients and families are increasingly navigating a complex landscape of providers. Understanding how Spravato® is intended to be used and how it should fit into a broader mental health treatment plan is essential when choosing a clinic you can trust.
What Is Spravato® Treatment and Who Is It For?
Spravato® treatment is typically considered for individuals diagnosed with treatment-resistant depression (TRD), a condition generally defined as major depressive disorder that has not responded adequately to at least two antidepressant trials given at appropriate dose and duration. Research shows that TRD is associated with higher symptom severity, greater functional impairment, and increased healthcare utilization, underscoring the need for careful, comprehensive treatment planning.
Clinical reviews emphasize that while definitions of treatment-resistant depression may vary slightly, the condition is widely recognized in psychiatric literature as requiring more advanced and closely monitored interventions than first-line treatments alone. Spravato® treatment is one such intervention, but it is not intended to replace therapy, psychiatric care, or structured treatment programs.
How Spravato® Treatment Is Intended to Be Administered
Spravato® is regulated through a Risk Evaluation and Mitigation Strategy (REMS) program established by the U.S. Food and Drug Administration. Under this program, Spravato® treatment must be administered in a certified healthcare setting, with patients monitored onsite for a minimum observation period following each dose. This requirement exists to ensure patient safety and to monitor potential side effects such as dissociation, sedation, and changes in blood pressure.
Spravato® is not a take-home medication, and patients are not permitted to drive themselves after treatment sessions. Peer-reviewed clinical literature reinforces the importance of this supervised model and ongoing clinical assessment throughout the course of treatment.
Concerning Trends as Spravato® Clinics Expand
As demand for Spravato® treatment has increased, a growing number of clinics have begun offering the medication without fully integrating it into comprehensive mental health care. Patients considering Spravato® treatment should be aware of potential red flags, including clinics that:
- Do not clearly explain or consistently provide the required observation after treatment
- Charge additional or unexpected fees for mandatory monitoring
- Offer minimal follow-up between sessions
- Market Spravato® as a quick or guaranteed solution
- Fail to assess whether patients may benefit from additional levels of care, such as IOP or PHP
- Provide limited transparency around insurance coverage and out-of-pocket costs
Research and patient reports indicate that when Spravato® treatment is positioned as a standalone or “fast fix,” patients may feel misled once they encounter the realities of treatment frequency, clinical oversight, and financial responsibility.
Why Integrated Care and Follow-Up Matter
Clinical guidance consistently emphasizes that Spravato® treatment is most effective when combined with ongoing psychiatric care and psychotherapy. Depression, particularly treatment-resistant depression, is rarely resolved through medication alone. Multimodal approaches that address biological, psychological, and behavioral factors are associated with more sustainable outcomes.
Studies and clinical reviews highlight the importance of integrating medication-assisted treatment with structured therapeutic support. For some patients, this may include referral to an Intensive Outpatient Program (IOP) or Partial Hospitalization Program (PHP) to provide additional stabilization, skill-building, and monitoring as part of a comprehensive care plan.
Clinics that do not evaluate or discuss these options risk offering incomplete treatment that may not adequately support long-term recovery.
Insurance Coverage and Transparency in Spravato® Treatment
Insurance coverage for Spravato® treatment varies significantly by payer and plan. While many behavioral health providers accept a broad range of insurance for therapy and structured programs, Spravato® coverage remains more limited and often requires prior authorization.
Responsible providers prioritize transparency by clearly explaining insurance requirements, potential out-of-pocket costs, and treatment expectations before care begins. This clarity helps patients make informed decisions and reduces frustration or financial stress during the course of treatment.
Skyway Behavioral Health’s Approach to Spravato® Treatment
At Skyway Behavioral Health, Spravato® treatment is offered as part of a clinically grounded, patient-centered continuum of care. Spravato® is not positioned as a one-time solution or isolated service, but as one tool among many that may support recovery when used thoughtfully and responsibly.
Skyway emphasizes safety, education, and long-term well-being by ensuring appropriate in-office monitoring, clear communication about the treatment process, and ongoing evaluation of each patient’s broader mental health needs. When clinically appropriate, Spravato® treatment is coordinated with therapy, psychiatric care, and structured programs such as IOP and PHP to support continuity of care beyond medication alone.
Questions to Ask Before Starting Spravato® Treatment
Patients considering Spravato® treatment may want to ask potential providers the following questions:
- How long is the required observation period, and is it included in the cost?
- How is follow-up care handled between treatment sessions?
- Will Spravato® treatment be coordinated with therapy or psychiatric services?
- What insurance plans are accepted, and what costs should I expect?
- If additional support is needed, will referrals to IOP or PHP be provided?
Providers that welcome these questions and answer them transparently are often better positioned to deliver responsible, ethical care.
General frequently asked questions about Spravato® treatment can be found here.
Choosing a Provider You Can Trust
Spravato® treatment can be a valuable option for individuals with treatment-resistant depression when delivered within a comprehensive, clinically responsible framework. Patients deserve providers who prioritize safety, transparency, and long-term recovery over convenience or volume. Skyway Behavioral Health remains committed to offering Spravato® treatment in a way that respects the complexity of depression and the trust patients place in their care team.
If you are interested in speaking with a Spravato® Concierge at Skyway Behavioral Health for yourself or a loved one, please click here.
